Suggested remit: To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Status In progress
Process STA
ID number 1192

Provisional Schedule

Expected publication 25 July 2018

Project Team

Project lead Marcia Miller

Email enquiries


Key events during the development of the guidance:

Date Update
21 June 2017 - 18 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance